Metis Global Partners LLC Has $1.11 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Metis Global Partners LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,727 shares of the biopharmaceutical company’s stock after purchasing an additional 347 shares during the period. Metis Global Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $1,112,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Huntington National Bank lifted its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $29,000. R Squared Ltd bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth $33,000. Washington Trust Advisors Inc. bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $42,000. Finally, True Wealth Design LLC raised its holdings in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,986 shares of company stock worth $20,397,849 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $243.53 on Tuesday. The firm has a market cap of $31.53 billion, a PE ratio of -112.23 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company’s 50-day moving average price is $254.32 and its two-hundred day moving average price is $262.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.